A-Alpha Bio raises $2.8M for genetically engineered drug discovery platform

The A-Alpha Bio team includes scientist Emily Engelhart, principal scientist David Colby, co-founder and CEO David Younger, co-founder and chief technology officer Randolph Lopez and engineering associate Charles Lin. (A-Alpha Bio Photo)

A Seattle startup that took root at the University of Washington has closed a $2.8 million

This post was originally published on this site


Check out https://contacted.org
%d bloggers like this: